Table 3.
Toxicity and performance status score by HIV status
| Variable | HIV-infected | HIV-uninfected | P |
|---|---|---|---|
| Hematologic values during treatment | |||
| Nadir hemoglobin level (g/dL), mean (SD) | 10.4 (1.79) | 10.4 (1.70) | 1.0 |
| Nadir ANC (×109/L) | 1.9 (1.58-2.85) | 2.16 (1.73-3.48) | .15 |
| Nadir WBC (×109/L) | 2.95 (2.39-4.03) | 3.12 (2.4-4.5) | .28 |
| Hematologic values at end of treatment | |||
| Hemoglobin (g/dL) | 10.7 (1.42) | 11 (1.67) | .23 |
| Renal function during treatment | |||
| Creatinine (μmol/L) | 52 (47-62) | 56 (47-64) | .40 |
| Renal function at the end of treatment | |||
| Creatinine (μmol/L) | 48 (41-54) | 53 (46-66) | .008 |
| Grade ≥2 nonhematologic toxicity during treatment | |||
| Fatigue | 12 (12.6) | 6 (12.8) | .98 |
| Weight loss | 6 (6.3) | 7 (14.9) | .10 |
| Urinary | 6 (6.3) | 3 (6.4) | .99 |
| Dermatitis | 52 (55.3) | 27 (57.4) | .81 |
| Gastrointestinal | 52 (54.7) | 26 (55.3) | .95 |
| Minimum performance status (KPS) | .16 | ||
| ≥90 | 40 (42.1) | 14 (29.8) | |
| <90 | 55 (57.9) | 33 (70.2) |